Title : Prototyping and evaluating a novel humanoid chewing robot for drug delivery using a medicated chewing gum
The global pharmaceutical market in 2009 was estimated at $837 billion and the US had a largest market share worth $300 billion per annum. It is estimated that the market could be worth nearly $1.6 trillion by 2020. The global drug delivery market in 2016 was estimated to be worth $510 billion which is a third of the estimated global pharmaceutical market. It is expected that the drug delivery market will be increased to around $900 billion by the year 2025. Medicated chewing gum (MCG) is a new advanced drug delivery method, with a promising future. Its potential has not yet been fully exploited because there is no gold standard methodology currently exists for testing chewing gum dissolution and current in-vitro apparatus/chewing machines cannot simulate the human chewing action and forces accurately to influence drug release rate because of the complexities involved in mastication. Also, most of these devices do not have the ability to combine mastication, saliva and chewing gum similar to human and subsequently measure the release of compounds from chewing gums.
The aim of this study is to validate the use of the newly developed humanoid chewing simulator to extract xylitol from commercially available chewing gum by quantifying its release over time using human participants and in-vitro chewing.
Audience take away:
• Why is there no gold standard methodology that currently exists for testing chewing gum dissolution?
• Why the current in-vitro apparatus machine used for medicated chewing gum cannot simulate the human chewing action?
• Why is the mastication of two devices chosen by Ph.Eur.8,0.2.9.25 apparatus (A and B) not similar to real mastication?
• What is bionic engineering design and how could it help to develop advanced drug delivery systems?